AAV Vector-Mediated Gene Delivery to Substantia Nigra Dopamine Neurons: Implications for Gene Therapy and Disease Models

被引:49
|
作者
Albert, Katrina [1 ]
Voutilainen, Merja H. [1 ]
Domanskyi, Andrii [1 ]
Airavaara, Mikko [1 ]
机构
[1] Univ Helsinki, Inst Biotechnol, Helsinki 00014, Finland
来源
GENES | 2017年 / 8卷 / 02期
基金
芬兰科学院;
关键词
adeno-associated virus; alpha-synuclein; Parkinson's disease; substantia nigra; dopamine; neurotrophic factors; GDNF; striatum; gene therapy; GFP; ADENOASSOCIATED VIRUS VECTORS; CONVECTION-ENHANCED DELIVERY; ALPHA-SYNUCLEIN; PARKINSONS-DISEASE; RAT MODEL; NEUROTROPHIC FACTOR; TYROSINE-HYDROXYLASE; NIGROSTRIATAL SYSTEM; STRIATAL DELIVERY; VIRAL VECTORS;
D O I
10.3390/genes8020063
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Gene delivery using adeno-associated virus (AAV) vectors is a widely used method to transduce neurons in the brain, especially due to its safety, efficacy, and long-lasting expression. In addition, by varying AAV serotype, promotor, and titer, it is possible to affect the cell specificity of expression or the expression levels of the protein of interest. Dopamine neurons in the substantia nigra projecting to the striatum, comprising the nigrostriatal pathway, are involved in movement control and degenerate in Parkinson's disease. AAV-based gene targeting to the projection area of these neurons in the striatum has been studied extensively to induce the production of neurotrophic factors for disease-modifying therapies for Parkinson's disease. Much less emphasis has been put on AAV-based gene therapy targeting dopamine neurons in substantia nigra. We will review the literature related to targeting striatum and/or substantia nigra dopamine neurons using AAVs in order to express neuroprotective and neurorestorative molecules, as well as produce animal disease models of Parkinson's disease. We discuss difficulties in targeting substantia nigra dopamine neurons and their vulnerability to stress in general. Therefore, choosing a proper control for experimental work is not trivial. Since the axons along the nigrostriatal tract are the first to degenerate in Parkinson's disease, the location to deliver the therapy must be carefully considered. We also review studies using AAV--synuclein (-syn) to target substantia nigra dopamine neurons to produce an -syn overexpression disease model in rats. Though these studies are able to produce mild dopamine system degeneration in the striatum and substantia nigra and some behavioural effects, there are studies pointing to the toxicity of AAV-carrying green fluorescent protein (GFP), which is often used as a control. Therefore, we discuss the potential difficulties in overexpressing proteins in general in the substantia nigra.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] In utero AAV vector-mediated gene delivery to the retina
    Surace, EM
    Auricchio, A
    Reich, SJ
    Pineles, S
    O'Connor, E
    Wilson, JM
    Bennett, J
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2002, 43 : U1310 - U1310
  • [2] Adenovirus vector-mediated delivery of the tyrosine hydroxylase gene into striatal cells: Implications for gene therapy in Parkinson's disease
    Freese, A
    Davidson, B
    OConnor, WM
    Lowen, G
    OConnor, M
    Kaplitt, M
    During, MJ
    [J]. JOURNAL OF NEUROSURGERY, 1996, 84 (02) : 742 - 742
  • [3] Comparison of different promoters to improve AAV vector-mediated gene therapy for neuronopathic Gaucher disease
    Massaro, Giulia
    Geard, Amy F.
    Nelvagal, Hemanth R.
    Gore, Katrina
    Clemo, Nadine K.
    Waddington, Simon N.
    Rahim, Ahad A.
    [J]. HUMAN MOLECULAR GENETICS, 2024, 33 (17) : 1467 - 1480
  • [4] AAV vector-mediated gene transfer to the brain of the cat
    Vite, CH
    Passini, MA
    McGowan, JC
    Poptani, H
    Polesky, AC
    Chambers, B
    O'Donnell, P
    Salvetti, A
    Haskins, ME
    Wolfe, JH
    [J]. MOLECULAR THERAPY, 2003, 7 (05) : S93 - S93
  • [5] Recombinant AAV Vector-Mediated Gene Delivery for the Potential Treatment of Adenosine Deaminase Deficiency
    Silver, Jared
    Jayandharan, Giridhara R.
    Cruz, Pedro
    Zhong, Li
    Elder, Melissa
    Srivastava, Arun
    Flotte, Terence R.
    [J]. MOLECULAR THERAPY, 2009, 17 : S117 - S117
  • [6] Viral vector-mediated gene therapy for Parkinson's disease
    Emborg, ME
    Deglon, N
    Leventhal, L
    Aebischer, P
    Kordower, JH
    [J]. CLINICAL NEUROSCIENCE RESEARCH, 2001, 1 (06) : 496 - 506
  • [7] AAV vector-mediated gene transfer into canine skeletal muscle
    Yuasa, K
    Yoshimura, M
    Nishiyama, A
    Ikemoto, M
    Ohshima, S
    Miyagoe-Suzuki, Y
    Howell, JM
    Hijikata, T
    Takeda, S
    [J]. JOURNAL OF GENE MEDICINE, 2006, 8 (03): : 390 - 390
  • [8] Pseudotyped AAV Vector-Mediated Gene Transfer in a Human Fetal Trachea Xenograft Model: Implications for In Utero Gene Therapy for Cystic Fibrosis
    Keswani, Sundeep G.
    Balaji, Swathi
    Le, Louis
    Leung, Alice
    Katz, Anna B.
    Lim, Foong-Yen
    Habli, Mounira
    Jones, Helen N.
    Wilson, James M.
    Crombleholme, Timothy M.
    [J]. PLOS ONE, 2012, 7 (08):
  • [9] Oncoretroviral and lentiviral vector-mediated gene therapy
    VandenDriessche, T
    Naldini, L
    Collen, D
    Chuah, MKL
    [J]. GENE THERAPY METHODS, 2002, 346 : 573 - 589
  • [10] Efficacious Androgen Hormone Administration in Combination with AAV Vector-Mediated Gene Therapy in Female Mice with Pompe Disease
    Han, Sang-oh
    Mapatano, Sweet Hope
    Li, Songtao
    Brooks, Elizabeth
    Koeberl, Dwight
    [J]. MOLECULAR THERAPY, 2017, 25 (05) : 193 - 194